Catalyst Dossier · compiled by CeliA 🧫

BeiGene, Ltd. (BGNE)

Biotechnology · market cap —

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-10-18 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-10-18 (est.)Phase 2 · BGB-45035imp 7/10
2026-11-15 (est.)Phase 2 · Tislelizumab (BGB-A317)imp 7/10
2027-03-15 (est.)Phase 3 · bendamustineimp 9/10
2027-06-15 (est.)Phase 2 · Zanubrutinibimp 7/10
2027-06-30 (est.)Phase 3 · Fluorouracil (5-FU)imp 9/10
2027-06-30 (est.)Phase 3 · Gemcitabine Hydrochlorideimp 9/10
2027-06-30 (est.)Phase 3 · BGB-A425imp 9/10
2027-06-30 (est.)Phase 3 · Paclitaxelimp 9/10

Pipeline

Asset	Phase	Indication
LBL-007	Phase 2	Non-small Cell Lung Cancer
Cisplatin	Phase 3	Esophageal Squamous Cell Carcinoma (ESCC)
Pemetrexed	Phase 2	Non Small Cell Lung Cancer
Oxaliplatin	Phase 3	Gastric, or Gastroesophageal Junction Adenocarcinoma
Gemcitabine Hydrochloride	Phase 3	Urothelial Carcinoma
Capecitabine	Phase 2	Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Venetoclax	Phase 3	Chronic Lymphocytic Leukemia
Carboplatin	Phase 3	Non-Small Cell Lung Cancer
Tislelizumab	Phase 3	Urothelial Carcinoma
Tislelizumab (BGB-A317)	Phase 2	MSI-H/dMMR Solid Tumors
Cisplatin injection	Phase 3	Non Small Cell Lung Cancer
Zanubrutinib	Phase 3	Refractory Mantle Cell Lymphoma
BGB-10188	Phase 2	Chronic Lymphocytic Leukemia
Docetaxel	Phase 3	Non-small Cell Lung Cancer
BGB-A445	Phase 2	Non-Small Cell Lung Cancer
Irinotecan	Phase 3	Esophageal Squamous Cell Carcinoma (ESCC)
Azacitidine	Phase 2	Acute Myeloid Leukemia
BGB-A425	Phase 2	Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2
lenvatinib	Phase 2	Advanced Solid Tumor
5-FU	Phase 2	Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for BGNE (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.